This leads to my old question, hopefully one for the forthcoming 2020 virtual AGM - what happened to MPC-300-IV? It showed evidence of action against both Diabetes [T2] and Rheumatoid Arthritis - two very significant markets and it would seem, given MSB's existing PhIII trials are maturing rapidly, bringing it into the home-straight of clinical development, would now seem logical? I know the Prof himself is particularly exited about what he sees as our potentially, most significant application [pre-Covid]. MPC-300-IV would be application to many diseases.
Maybe MSB see Remestemcel-L as a viable stand-in, in those types of applications used "off label"?
This leads to my old question, hopefully one for the forthcoming...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
-0.005(0.44%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.12 | $1.166M | 1.027M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 59092 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 16812 | 7 |
View Market Depth
| Last trade - 10.29am 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |